Alopecia

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.

This study highlighted VTE risk factors in a cohort of patients with alopecia areata who were eligible for baricitinib treatment.

This Month in Review summary includes a list of some of the most notable stories in the dermatology field from August 2025.

In this analysis, a variety of alternative therapies for hair loss, such as oils, stem cells, and laser treatments, were highlighted for their potential.

Oral supplementation with a novel dietary AGA-P supplement was shown to increase the clinical efficacy of pharmacological treatments for androgenic alopecia.

This study highlights a significant link between alopecia areata and autoimmune thyroid disease, assessing a large-scale and diverse population.

This study highlights an approach to male pattern baldness using a topical dimethylglycine sodium salt (DMG-Na) and caffeine-containing shampoo.

Providing nurses and MAs with an educational video on standardized hair loss photo techniques increased the quantity and quality of documented pictures.

In a Chinese cohort, baricitinib achieved high hair regrowth rates in alopecia areata, totalis, universalis, and eyebrow/eyelash loss, with no serious adverse events.

This summary covers a variety of notable DERM 2025 conference news highlights, specifically in the area of alopecia areata.

These pooled THRIVE-AA1 and THRIVE-AA2 study data highlight improvements in mental health among patients with alopecia given deuruxolitinib.

This session was titled ‘The Hidden Undercurrent: When Hair Loss Isn’t Alopecia Areata’ and was presented at the DERM 2025 conference by April Armstrong, MD, MPH.

Topline results from the first of 2 studies in the UP-AA program show upadacitinib 15 mg and 30 mg met the primary endpoint for scalp hair coverage.

Elkady joins the program to discuss her experience transitioning from patient care to clinical trials and industry.

This summary highlights changes in severe alopecia areata following deuruxolitinib therapy during THRIVE-AA1 and THRIVE-AA2.

This summary of the phase 3 ALLEGRO-LT study highlights several notable findings on ritlecitinib’s use among adults and adolescents with alopecia areata.

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

This analysis highlights differences between topical and oral finasteride for hair loss, specifically looking at adverse events and any causal connections.

Alopecia significantly impacts life quality, with stigma and negative perceptions contributing to mental health issues such as anxiety and depression.

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

New research reveals significant links between alopecia areata and mental health issues, emphasizing the need for comprehensive care in affected individuals.